BridgeMD
New treatment option for Central Post-Stroke Pain
Official title Treatment of Post-Stroke Central Pain
ClinicalTrials.gov ID: NCT07593313
What this study is testing
What is Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)?
Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline) is an investigational medicine, being studied as a potential treatment for central post-stroke pain.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To evaluate the short-term analgesic efficacy of stSCS combined with pharmacotherapy compared with pharmacotherapy alone in patients with CPSP, measured by Numerical Rating Scale (NRS) score immediately after treatment.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of central post-stroke pain (CPSP) according to the International Association for the Study of Pain (IASP) criteria
- Clear history of stroke confirmed by cranial CT or MRI
- Pain occurring after stroke and distributed in body parts corresponding to central nervous system injury
- Pain with neuropathic characteristics (e.g., burning sensation, electric shock sensation, needle prick sensation)
- Pain not explained by other causes
You likely can't join if
- History of chronic pain before stroke
- Severe cognitive impairment that prevents cooperation with pain assessment (Mini-Mental State Examination, MMSE \< 15 points)
- Contraindications to spinal cord stimulation (SCS), such as coagulation disorders, active infections, or mental diseases that prevent cooperation
- Malignant tumors or other severe organic diseases with expected survival \< 1 year
See the full eligibility criteria
- Diagnosis of central post-stroke pain (CPSP) according to the International Association for the Study of Pain (IASP) criteria
- Clear history of stroke confirmed by cranial CT or MRI
- Pain occurring after stroke and distributed in body parts corresponding to central nervous system injury
- Pain with neuropathic characteristics (e.g., burning sensation, electric shock sensation, needle prick sensation)
- Pain not explained by other causes
- Age ≥ 18 years
- Pain duration ≥ 3 months
- Baseline pain Numerical Rating Scale (NRS) score ≥ 4 points
- Complete clinical data with follow-up time ≥ 6 months
- History of chronic pain before stroke
- Severe cognitive impairment that prevents cooperation with pain assessment (Mini-Mental State Examination, MMSE \< 15 points)
- Contraindications to spinal cord stimulation (SCS), such as coagulation disorders, active infections, or mental diseases that prevent cooperation
- Malignant tumors or other severe organic diseases with expected survival \< 1 year
The study team makes the final eligibility decision.
Where it's taking place
- Nanchong, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanchong, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.